Freenome IPO
Freenome is a biotechnology company developing blood-based tests for early cancer detection using artificial intelligence and genomics. The company's platform aims to detect cancer before symptoms appear, which could significantly improve patient outcomes and represents a large market opportunity in precision medicine.
What We Know
Freenome remains a private company and has not announced any IPO plans. The company has raised substantial venture funding, including a Series C round that reportedly valued the company at over $1 billion, achieving unicorn status in the competitive cancer diagnostics space. While the company's technology and market potential could make it an attractive IPO candidate, no confirmed details about timing or plans have been disclosed. The regulatory pathway for cancer screening tests can be lengthy, and companies in this space often wait until they have significant clinical validation before going public.
Frequently Asked Questions
Has Freenome had an IPO?
No, Freenome has not had an IPO and remains privately held. The company has not announced any plans to go public.
When is the Freenome IPO date?
There is no confirmed IPO date for Freenome as the company has not announced plans to go public. Sign up for alerts to stay informed.
How can I buy Freenome stock?
You cannot currently buy Freenome stock as it is privately held and not available on public markets. Sign up for alerts to stay informed.
Stay Updated on the Freenome IPO
Get real-time alerts when Freenome files for an IPO, prices shares, or begins trading.
Get IPO Alerts